Breast Cancer DX: Is there a Market Here?
Executive Summary
The discovery of a gene associated with hereditary breast cancer opens up the potential for widespread predisposition-to-disease testing. But other areas of breast cancer diagnostics are also seeing a flurry of activity, notably new tumor markers for detecting recurrence and prognosis of disease.
You may also be interested in...
Applying the Cytyc Formula to Breast Cancer
With its acquisition of Pro-Duct Health, Cytyc is hoping to transfer its very successful performance with the ThinPrep Pap Test to the field of ductal lavage for breast cancer risk assessment. Cytyc is paying $167.5 million for Pro-Duct, which has sales of less than $1 million. But Cytyc believes ductal lavage represents a multi-billion dollar opportunity with no direct competition. Physicians are excited about the procedure--although they caution a lot of data needs to be compiled to determine the utility of information provided by ductal lavage.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.